US 11,944,308 B2
Compressible adjunct with crossing spacer fibers
Michael J. Vendely, Lebanon, OH (US); Frederick E. Shelton, IV, Hillsboro, OH (US); Jason L. Harris, Lebanon, OH (US); Charles J. Scheib, Loveland, OH (US); Howell T. Goldrein, Cambridge (GB); Robert S. Moir, Cambridge (GB); Sofia Maria Consonni, Birmingham (GB); Ismail Akram, Cambridge (GB); Ashley D. Easter, Cambridge (GB); and Helen S. Latham, Cambridge (GB)
Assigned to Cilag GmbH International, Zug (CH)
Filed by Cilag GmbH International, Zug (CH)
Filed on Dec. 14, 2022, as Appl. No. 18/081,335.
Application 18/081,335 is a continuation of application No. 17/186,335, filed on Feb. 26, 2021, granted, now 11,712,244.
Application 17/186,335 is a continuation of application No. 16/229,607, filed on Dec. 21, 2018, granted, now 10,932,779, issued on Mar. 2, 2021.
Application 16/229,607 is a continuation of application No. 14/871,071, filed on Sep. 30, 2015, granted, now 10,433,846, issued on Oct. 8, 2019.
Prior Publication US 2023/0255631 A1, Aug. 17, 2023
Int. Cl. A61B 17/072 (2006.01); A61B 17/00 (2006.01); A61B 17/064 (2006.01); A61B 17/068 (2006.01); A61B 17/08 (2006.01); A61B 17/10 (2006.01); A61B 17/32 (2006.01); A61L 17/10 (2006.01); A61L 17/12 (2006.01); B05D 1/00 (2006.01); B05D 1/30 (2006.01); B29C 48/16 (2019.01); B32B 3/02 (2006.01); B32B 3/08 (2006.01); B32B 3/20 (2006.01); B32B 3/26 (2006.01); B32B 5/02 (2006.01); B32B 5/10 (2006.01); B32B 5/12 (2006.01); B32B 5/18 (2006.01); B32B 5/24 (2006.01); B32B 5/26 (2006.01); B32B 7/05 (2019.01); D01D 5/00 (2006.01); D01D 5/18 (2006.01); D04H 1/56 (2006.01); B29C 44/34 (2006.01); B29C 48/00 (2019.01); B29C 48/05 (2019.01); B29L 31/00 (2006.01)
CPC A61B 17/105 (2013.01) [A61B 17/00491 (2013.01); A61B 17/0644 (2013.01); A61B 17/068 (2013.01); A61B 17/072 (2013.01); A61B 17/07207 (2013.01); A61B 17/07292 (2013.01); A61B 17/08 (2013.01); A61B 17/32 (2013.01); A61L 17/105 (2013.01); A61L 17/12 (2013.01); B05D 1/007 (2013.01); B05D 1/30 (2013.01); B29C 48/16 (2019.02); B32B 3/02 (2013.01); B32B 3/08 (2013.01); B32B 3/20 (2013.01); B32B 3/266 (2013.01); B32B 5/024 (2013.01); B32B 5/026 (2013.01); B32B 5/10 (2013.01); B32B 5/12 (2013.01); B32B 5/18 (2013.01); B32B 5/245 (2013.01); B32B 5/26 (2013.01); B32B 7/05 (2019.01); D01D 5/0023 (2013.01); D01D 5/18 (2013.01); D04H 1/565 (2013.01); A61B 2017/00004 (2013.01); A61B 2017/00477 (2013.01); A61B 2017/00526 (2013.01); A61B 2017/00831 (2013.01); A61B 2017/00862 (2013.01); A61B 2017/00893 (2013.01); A61B 2017/00955 (2013.01); A61B 2017/00964 (2013.01); A61B 2017/07214 (2013.01); A61B 2017/07221 (2013.01); A61B 2017/07228 (2013.01); A61B 2017/07235 (2013.01); A61B 2017/07242 (2013.01); A61B 2017/0725 (2013.01); A61B 2017/07257 (2013.01); A61B 2017/07271 (2013.01); A61B 2017/07278 (2013.01); A61B 2017/07285 (2013.01); A61L 2420/02 (2013.01); B29C 44/3453 (2013.01); B29C 44/358 (2013.01); B29C 48/0012 (2019.02); B29C 48/0022 (2019.02); B29C 48/05 (2019.02); B29L 2031/753 (2013.01); B29L 2031/7546 (2013.01); B32B 2250/03 (2013.01); B32B 2250/40 (2013.01); B32B 2307/50 (2013.01); B32B 2307/54 (2013.01); B32B 2307/72 (2013.01); B32B 2307/732 (2013.01); B32B 2307/736 (2013.01); B32B 2535/00 (2013.01); D10B 2331/041 (2013.01); D10B 2509/00 (2013.01)] 20 Claims
OG exemplary drawing
 
1. An adjunct, comprising:
a first layer to interface with a staple cartridge;
a second layer to interface with tissue, wherein the first layer and the second layer are configurable between:
an uncompressed state in which a first space is defined between the first layer and the second layer; and
a compressed state in which a second space less than the first space is defined between the first layer and the second layer; and
a support layer intermediate the first layer and the second layer, wherein the support layer comprises walls that define cavities within the support layer, and wherein the cavities are interconnected;
wherein the adjunct comprises a polymeric composition that comprises a pharmaceutical agent, wherein the pharmaceutical agent is to be released from the polymeric composition to effect tissue healing at a faster rate than without the pharmaceutical agent.